From the Department of Cornea and Anterior Segment, Instituto de Microcirugia Ocular, Barcelona, Spain (Papa-Vettorazzi); Department of Cornea and Refractive Surgery, Instituto de Microcirugia Ocular, Barcelona, Spain (Güell, Moura-Coelho, Elies); Texas Tech University Health Sciences Centre, El Paso, Lubbock, Texas (Cruz-Rodriguez).
J Cataract Refract Surg. 2022 Jul 1;48(7):813-818. doi: 10.1097/j.jcrs.0000000000000848.
To evaluate long-term efficacy, safety, predictability, and stability of a posterior chamber phakic intraocular lens (Visian implantable collamer lens [ICL]) in eyes with ≥10 years of follow-up.
Instituto de Microcirugía Ocular, Barcelona, Spain.
Retrospective study.
Eyes undergoing ICL implantation from 2008 to 2011 with ≥10 years of follow-up were included. Variables analyzed were preoperative, 1-month, 1-year, 5-year, and last follow-up uncorrected distance (UDVA) and corrected distance visual acuity (CDVA), manifest refraction, spherical equivalent (SE), endothelial cell count (ECC), and intraocular pressure (IOP). Descriptive statistics were performed and results reported following the Standard for Reporting Refractive Surgery Outcomes.
45 eyes (26 patients) were analyzed; the mean follow-up 11.35 ± 1.30 years. The mean preoperative SE was -10.06 ± 3.40 diopters (D) and the mean preoperative cylinder -1.55 ± 1.45 D. At the last follow-up, efficacy and safety indices were 0.79 and 1.12, respectively. In total, 32 eyes (71%) achieved an UDVA of ≥20/40. 22 eyes (49%) gained ≥1 line of CDVA, and 2 eyes (4%) lost ≥2 lines of CDVA. At the final follow-up, 19 eyes (42%) and 29 eyes (64%) were within ±0.50 D and ±1.00 D of attempted SE correction, respectively. 31 eyes (69%) had ≤1.00 D of postoperative astigmatism, and 29 eyes (74%) were within ±15 degrees from the intended correction axis. At the last visit, a statistically significant myopic progression of -0.75 ± 1.20 D was observed ( P = .01). ECC loss at the last follow-up was 9.85 ± 11.35%. IOP remained stable. There were no intraoperative complications. 3 eyes (7%) developed cataract after 10 years.
The long-term results demonstrated that ICL was effective, predictable, stable, and safe.
评估后房型有晶状体眼人工晶状体（Visian 可植入 Collamer 透镜 [ICL]）在随访时间≥10 年的患者中的长期疗效、安全性、可预测性和稳定性。
西班牙巴塞罗那眼科微手术研究所。
回顾性研究。
纳入 2008 年至 2011 年间接受 ICL 植入术且随访时间≥10 年的患者。分析的变量包括术前、术后 1 个月、1 年、5 年和末次随访时的未矫正远视力（UDVA）和矫正远视力（CDVA）、客观屈光、等效球镜（SE）、内皮细胞计数（ECC）和眼内压（IOP）。采用描述性统计学方法，结果根据屈光手术结果报告标准进行报告。
共分析了 45 只眼（26 例患者），平均随访时间为 11.35±1.30 年。术前 SE 的平均值为-10.06±3.40 屈光度（D），术前平均柱镜值为-1.55±1.45 D。末次随访时，有效性和安全性指数分别为 0.79 和 1.12。共有 32 只眼（71%）获得了≥20/40 的 UDVA。22 只眼（49%）获得了≥1 行的 CDVA 提高，2 只眼（4%）丧失了≥2 行的 CDVA。末次随访时，19 只眼（42%）和 29 只眼（64%）达到了 SE 矫正目标值的±0.50 D 和±1.00 D 以内。31 只眼（69%）术后散光值≤1.00 D，29 只眼（74%）的散光轴与目标轴的偏差在±15 度以内。末次随访时，观察到 SE 存在统计学意义的近视进展，平均为-0.75±1.20 D（P=.01）。末次随访时 ECC 丢失率为 9.85±11.35%。IOP 保持稳定。术中无并发症发生。3 只眼（7%）在 10 年后出现白内障。
长期结果表明，ICL 是一种有效、可预测、稳定且安全的治疗方法。
